

## Radiotherapy for Pediatric Tumors

Guest Editors:

**Dr. Kevin X. Liu**

Department of Radiation  
Oncology, Brigham and Women's  
Hospital, Dana-Farber Cancer  
Institute, Boston Children's  
Hospital, Harvard Medical  
School, Boston, MA 02115, USA

**Dr. Nicholas DeNunzio**

Department of Radiation  
Oncology, Rutgers Cancer  
Institute of New Jersey, 195 Little  
Albany Street, New Brunswick, NJ  
08901, USA

Deadline for manuscript  
submissions:

**31 July 2025**


### Message from the Guest Editors

Dear Colleagues,

Radiotherapy plays an important role in the treatment of many pediatric tumors. Radiation treatment can improve local control and is critical in curing certain types of pediatric malignancies. In recent decades, advances in radiation technology and planning have contributed to improvements in outcomes, including the reduction in toxicity. Future research is underway to investigate new strategies to improve local control and survival in pediatric tumors with poor prognosis and decrease acute and long-term toxicity after radiation.

This Special Issue will seek to explore interesting and challenging questions from a wide range of topics, including, but not limited to, the following: clinical outcomes after radiotherapy, including toxicity; the development of novel radiotherapy treatment paradigms; preclinical research to identify new radiosensitizers; and long-term survivorship care after radiation treatment within the context of pediatric tumors. In this Special Issue, original research articles and reviews are welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

## Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **MEDLINE**, **PMC**, **Embase**, and **other databases**.

**Journal Rank:** JCR - Q2 (Oncology)

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

## Contact Us

Current Oncology Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/currentoncology](https://mdpi.com/journal/currentoncology)  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)  
[X@CurrentOncology](https://twitter.com/CurrentOncology)